The Pharma Letter

28/02/2022

The week in pharma: action, reaction and insight – week to February 25, 2022 -

Among significant news last week, US biotech Synairgen’s COVID-19 therapy SNG001 missed endpoints in a Phase III study of hospitalized patients. BioNTech announced a deal with fellow German company Medigene for the discovery of cancer immunotherapeutics. Sanofi and GlaxoSmithKline have now develop...

21/02/2022

The week in pharma: action, reaction and insight – week to February 18, 2022 -

The long-awaited confirmation from the US Senate of Robert Califf’s nomination to become Food and Drug Administration Commissioner was announced last Tuesday, but on a tight vote. On the research front, Sage Therapeutics and Biogen announced confident results for their depressive disorder candidat...

14/02/2022

The week in pharma: action, reaction and insight – week to February 11, 2022 -

Research news last week saw US cancer focussed firm Karyopharm Therapeutics release a bullish review of new Phase III data on its endometrial cancer candidate selinexor. Financial results were also in focus. Pfizer, the world’s largest prescription medicines maker last Tuesday reported record four...

07/02/2022

The week in pharma: action, reaction and insight – week to February 4, 2022 -

Among last week’s notable news, Pfizer and Ionis pulled the plug on the development of their cholesterol candidate vupanorsen, with rights to the drug returned to Ionis. US biotech Biogen last week exercised its option to co-develop cancer candidate mosunetuzumab, paying Roche a one-time fee of $3...

31/01/2022

The week in pharma: action, reaction and insight – week to January 28, 2022 -

With the fourth-quarter financial results season starting, Johnson & Johnson, as ever, was the first big pharma to release figures on Tuesday, and these beat expectations. US biotech Incyte last Tuesday announced a clinical setback for its parsaclisib trial and decision to opt out of continued devel...

24/01/2022

The week in pharma: action, reaction and insight – week to January 21, 2022 -

Last week’s notable announcements included Swiss pharma giant Roche saying it has regenerated a previously dropped compound, tominersen - licensed from Ionis Pharmaceuticals, to develop it for Huntington’s disease. Belgium’s biggest pharma firm UCB announced a takeover bid worth up to $1.9 bil...

17/01/2022

The week in pharma: action, reaction and insight – week to January 14, 2022 -

Among last week’s notable announcements, US pharma giant Pfizer said it has entered into a gene base editing collaboration with Beam Therapeutics, which involves an upfront $300 million and up to $1.35 billion in milestones. Germany’s Bayer moved further into cell and gene therapies, announcing ...

10/01/2022

The week in pharma: action, reaction and insight – week to January 7, 2022 -

Licensing deals featured prominently in last week’s news, starting with Biogen last Tuesday saying it has exercised an option for rights to Ionis Pharmaceuticals’ BIIB115/ION306 for spinal muscular atrophy. Then US biotech giant Amgen inked an up to $1.9 billion agreement with machine learning s...

20/12/2021

The week in pharma: action, reaction and insight - week to December 17, 2021 -

Last week saw more M&A announcements, first with Pfizer revealing its planned acquisition of Arena Pharmaceuticals for $6.7 billion, with the aim of expanding its immune-inflammatory portfolio including etrasimod, then with Australia’s CSL Limited confirming rumors that it will take over Swiss fir...

15/01/2021

The transition to : what's next for the UK’s pharmaceutical industry? https://www.thepharmaletter.com/article/the-transition-to-brexit-what-s-next-for-the-uk-s-pharmaceutical-industry

14/01/2021

Despite COVID-19, biopharma still pushed ahead with M&A in 2020 https://www.thepharmaletter.com/article/2020-m-a-table

18/06/2020

https://www.thepharmaletter.com/article/india-readies-1-3-billion-pharma-incentive-scheme-aims-to-be-120-billion-industry